Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Shenzhen Hepalink Rises 27% in First Trading Session

publication date: May 6, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Shenzhen Hepalink gained as much as 27% from its IPO price in its first trading session, hitting a high of 188 RMB ($27.65). The IPO was priced at 148 RMB ($21.76), which was already a pricey 72 times its 2009 earnings. Hepalink is the world’s leading producer of the blood thinner Heparin. Li Li and Li Tan, the founders of Hepalink, own 72% of the company, a stake that is now worth $7.6 billion. More details...



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners